HOUSTON, Feb. 20, 2024 /PRNewswire/ -- FibroBiologics (Nasdaq: FBLG) ("FibroBiologics") is a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development ...
FibroBiologics, Inc. Announces Investor Webinar on Innovative Fibroblast-Based Cell Therapy Platform
FibroBiologics, Inc., a clinical-stage biotechnology company focused on developing therapies for chronic diseases through fibroblasts, announced an investor webinar scheduled for July 10, 2025, at ...
Researchers at the Terasaki Institute for Biomedical Innovation and the University of Arizona College of Medicine have ...
NEW YORK (PIX11) – It is being called a game-changer in curing some of the world’s most crippling diseases and conditions. Technology developed by FibroBiologics is already proving in small trials to ...
FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results